Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


England’s Unused Innovative Medicines Fund Under Fire Again

Executive Summary

A group of UK academics have broadly welcomed the fund that will pay for innovative non-cancer drugs, but have expressed concern over issues such as the entry criteria and the definition of “high unmet need.” They also say safeguards are needed against possible financial loss to the National Health Service.

You may also be interested in...

England’s Innovative Medicines Fund Picks Up Pace As Alexion’s Kanuma Gets Green Light

Alexion has secured funding for its Wolman disease drug Kanuma via England’s Innovative Medicines Fund after several years of “constructive collaboration” with the country’s health technology assessment body NICE and the National Health Service.

NICE: New Proportionate Approach To HTAs ‘Flexible, But Not Bespoke’

NICE, the health technology assessment body for England and Wales, says its new proportionate approach to appraisals should be dynamic enough to “cope with the unique perspectives of new drugs” without being tailored to individual products or companies.

Industry Calls For Reform of England’s Unused Innovative Medicines Fund

The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts